Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • procedure : nonmyeloablative allogeneic hematopoietic cell transplant

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 75 Years

Inclusion Criteria

- Myelodysplastic Syndromes - Myeloproliferative Disorders - HLA matched donor available

External Links

Explore related trials

Contact information

Primary Contact:

BMT Referrals 6507230822

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: